Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica Target Development Services at Growing Inhalation Market

Published: Wednesday, October 16, 2013
Last Updated: Wednesday, October 16, 2013
Bookmark and Share
CDMO’s Nottingham site a hot bed of innovation with unique spray drying, powder filling and dry powder inhaler technology.

Aesica has announced its intention to increase its range of inhalation services and products in development, with a new Lead Technical Centre also envisaged in the near future.

A key part of this inhalation drive has been the company’s focus on the intake of skilled staff, coupled with the commercial development of several leading inhalation technologies and the company is actively partnering with other innovative companies and universities to discover and engineer new technologies for commercial applications.

Aesica currently has two new development technologies available to clients, including spray drying techniques delivered through a partnership with Upperton, and a powder filling technology delivered through 3P’s Fill2Weight.

The plan marks a systemic shift in the wider market with clients now looking for CDMOs to have a wider range of development technologies, delivery expertise and the ability to take a project right through to commercialization.

Another key factor in the company’s growth within this market has been the adoption of non IP protected products, which enables Aesica to concentrate with the client on developing the right formulation irrespective of delivery mechanism.

These new technologies have provided a huge advantage to customers in terms of lowering costs, particularly for re-formulations of generic products, whereby the cost of set-up is highly prohibitive to new market entrants and this is forecast to be a rapidly expanding sector.

Building on these successes Aesica is researching both internally and externally for new innovations in formulation technologies to complement its suite of services and it envisages opening a new inhalation Lead Technical Centre by the end of 2014.

The Nottingham site currently has over 5 years’ experience developing new generic inhalation products alongside many New Chemical Entities (NCE) for trial. Aesica is increasingly looking to work with clients over the longer term and is concentrating on taking new drug targets right through to commercial stage, with the ability to switch easily between initial nebulizer products (i.e. a low cost entry to early clinical trials) and dry powder inhalers for use in later clinical trials.

This flexible on-site approach also means that the company can reduce time to market with 24/7 capabilities, which has allowed the company to deliver on every client clinical date.

Ian Lafferty, Site Director for Aesica Nottingham, commented: “Inhalation is a rapidly growing market with many US companies looking to bring NCE production to Europe, whilst we also see a dramatic growth for products going into China and SE Asia, particularly amongst generic formulations. We have largely operated under the radar in terms of inhalation products despite the wealth of new technologies coming to market here and our intention is to take a lead in bringing products to market faster and developing the next generation of technologies through our Lead Technical Centre”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Appoints New Product Release Manager
Company announces appointment of Adam Burgess.
Wednesday, August 20, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Aesica Completes the Validation of its High Capacity Manufacturing Facility
$45m (USD) has been invested at its Queenborough, UK site.
Saturday, March 15, 2014
Aesica Appoints Ian Muir to Commercial Managing Director Position
Key functions centre on the Group’s commercial business and product pipeline development across API, formulation development and formulated products.
Tuesday, February 04, 2014
Aesica Awarded NEPIC Industry Award
Corporate HR Manager wins NEPIC 2014 Young Achiever Accolade within the Pharmaceutical category.
Thursday, January 30, 2014
Aesica Appoints New Site Manufacturing Manager at Cramlington Facility
Tasked with optimizing performance schedules, including 4 new products for 2014.
Tuesday, November 26, 2013
Aesica Recruits New East Coast Business Development Manager
Appointment of Baali Muganga to spearhead growth in contract manufacturing market share across the US region.
Tuesday, October 29, 2013
Aesica Unveils a New High Capacity Manufacturing Facility
New facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults.
Thursday, September 19, 2013
Aesica Appoints Bhavesh Kotecha to Newly Created Position of CSD
Role to oversee a Group wide services of IT, M&A process planning, health and safety, and internal audit system.
Thursday, August 29, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!